Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C Zacks Equity Research - Zacks Investment Research - Wed Jan 16, 9:05AM CST Zacks Equity Research - ZACKS - Wed Jan 16, 9:05AM CST
Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
What's in Store for Merck in 2019 After a Solid Run in '18? Zacks Equity Research - Zacks Investment Research - Mon Jan 14, 7:39AM CST Zacks Equity Research - ZACKS - Mon Jan 14, 7:39AM CST
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks Equity Research - Zacks Investment Research - Wed Jan 9, 9:04AM CST Zacks Equity Research - ZACKS - Wed Jan 9, 9:04AM CST
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff Zacks Equity Research - Zacks Investment Research - Mon Jan 7, 8:50AM CST Zacks Equity Research - ZACKS - Mon Jan 7, 8:50AM CST
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Sweta Killa - Zacks Investment Research - Mon Jan 7, 8:27AM CST Sweta Killa - ZACKS - Mon Jan 7, 8:27AM CST
Sector ETF report for PPH
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks Equity Research - Zacks Investment Research - Fri Jan 4, 9:07AM CST Zacks Equity Research - ZACKS - Fri Jan 4, 9:07AM CST
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Why the Earnings Surprise Streak Could Continue for Astrazeneca (AZN) Zacks Equity Research - Zacks Investment Research - Thu Jan 3, 9:10AM CST Zacks Equity Research - ZACKS - Thu Jan 3, 9:10AM CST
Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug Zacks Equity Research - Zacks Investment Research - Thu Dec 27, 5:06PM CST Zacks Equity Research - ZACKS - Thu Dec 27, 5:06PM CST
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019 Kinjel Shah - Zacks Investment Research - Thu Dec 27, 7:20AM CST Kinjel Shah - ZACKS - Thu Dec 27, 7:20AM CST
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug...
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca Zacks Equity Research - Zacks Investment Research - Mon Dec 24, 7:07AM CST Zacks Equity Research - ZACKS - Mon Dec 24, 7:07AM CST
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca
Top Research Reports for Procter & Gamble, Oracle & United Parcel Service Mark Vickery - Zacks Investment Research - Fri Dec 21, 12:36PM CST Mark Vickery - ZACKS - Fri Dec 21, 12:36PM CST
Top Research Reports for Procter & Gamble, Oracle & United Parcel Service
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations Zacks Equity Research - Zacks Investment Research - Fri Dec 21, 8:13AM CST Zacks Equity Research - ZACKS - Fri Dec 21, 8:13AM CST
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting Zacks Equity Research - Zacks Investment Research - Thu Dec 20, 4:34PM CST Zacks Equity Research - ZACKS - Thu Dec 20, 4:34PM CST
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base Zacks Equity Research - Zacks Investment Research - Thu Dec 20, 7:38AM CST Zacks Equity Research - ZACKS - Thu Dec 20, 7:38AM CST
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.
Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia BusinessWire - Thu Dec 20, 6:00AM CST CMTX - Thu Dec 20, 6:00AM CST
--ROCKIES demonstrated a statistically-significant improvement in hemoglobin vs. epoetin alfa in dialysis-dependent patients
LYNPARZA(R) (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer BusinessWire - Wed Dec 19, 3:01PM CST CMTX - Wed Dec 19, 3:01PM CST
--First PARP inhibitor approved in 1st-line maintenance for BRCAm advanced ovarian cancer
BMY vs. AZN: Which Stock Should Value Investors Buy Now? Zacks Equity Research - Zacks Investment Research - Tue Dec 18, 8:30AM CST Zacks Equity Research - ZACKS - Tue Dec 18, 8:30AM CST
BMY vs. AZN: Which Stock Is the Better Value Option?
Merck to Acquire Europe's Antelliq Group for $2.4 Billion Zacks Equity Research - Zacks Investment Research - Mon Dec 17, 2:22PM CST Zacks Equity Research - ZACKS - Mon Dec 17, 2:22PM CST
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases PR Newswire - Mon Dec 17, 6:00AM CST CMTX - Mon Dec 17, 6:00AM CST
Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an...
